TY - JOUR
T1 - Ionising radiation and risk of death from leukaemia and lymphoma in radiation-monitored workers (INWORKS)
T2 - An international cohort study
AU - Leuraud, Klervi
AU - Richardson, David B.
AU - Cardis, Elisabeth
AU - Daniels, Robert D.
AU - Gillies, Michael
AU - O'Hagan, Jacqueline A.
AU - Hamra, Ghassan B.
AU - Haylock, Richard
AU - Laurier, Dominique
AU - Moissonnier, Monika
AU - Schubauer-Berigan, Mary K.
AU - Thierry-Chef, Isabelle
AU - Kesminiene, Ausrele
N1 - Funding Information:
This work was partly funded by the Centers for Disease Control and Prevention ( 5R03 0H010056-02 ) and the Ministry of Health, Labour and Welfare of Japan (GA No 2012-02-21-01 ). The construction of the French cohort was realised by the Institut de Radioprotection et de Sûreté Nucléaire, with partial funding from AREVA and Electricité de France . The Institut de Radioprotection et de Sûreté Nucléaire thanks all people from the French Atomic Energy Commission, AREVA, and Electricité de France who cooperated in the elaboration of the French cohort. For the US contribution, funding was provided by the National Institute for Occupational Safety and Health , by the US Department of Energy through an agreement with the US Department of Health and Human Services , and through a grant received by the University of North Carolina from the National Institute for Occupational Safety and Health ( R03 OH-010056 ). The construction of the UK cohort was undertaken by Public Health England who operate the UK's National Registry for Radiation Workers. Public Health England thank all of the organisations and individuals participating in the National Registry for Radiation Workers for their cooperation, and the National Registry for Radiation Workers steering group for their continued support. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health.
Publisher Copyright:
© 2015 Leuraud et al. Open Access article distributed under the terms of CC BY-NC-ND.
PY - 2015
Y1 - 2015
N2 - Background: There is much uncertainty about the risks of leukaemia and lymphoma after repeated or protracted low-dose radiation exposure typical of occupational, environmental, and diagnostic medical settings. We quantified associations between protracted low-dose radiation exposures and leukaemia, lymphoma, and multiple myeloma mortality among radiation-monitored adults employed in France, the UK, and the USA. Methods: We assembled a cohort of 308 297 radiation-monitored workers employed for at least 1 year by the Atomic Energy Commission, AREVA Nuclear Cycle, or the National Electricity Company in France, the Departments of Energy and Defence in the USA, and nuclear industry employers included in the National Registry for Radiation Workers in the UK. The cohort was followed up for a total of 8·22 million person-years. We ascertained deaths caused by leukaemia, lymphoma, and multiple myeloma. We used Poisson regression to quantify associations between estimated red bone marrow absorbed dose and leukaemia and lymphoma mortality. Findings: Doses were accrued at very low rates (mean 1·1 mGy per year, SD 2·6). The excess relative risk of leukaemia mortality (excluding chronic lymphocytic leukaemia) was 2·96 per Gy (90% CI 1·17-5·21; lagged 2 years), most notably because of an association between radiation dose and mortality from chronic myeloid leukaemia (excess relative risk per Gy 10·45, 90% CI 4·48-19·65). Interpretation: This study provides strong evidence of positive associations between protracted low-dose radiation exposure and leukaemia. Funding: Centers for Disease Control and Prevention, Ministry of Health, Labour and Welfare of Japan, Institut de Radioprotection et de SÛreté Nucléaire, AREVA, Electricité de France, National Institute for Occupational Safety and Health, US Department of Energy, US Department of Health and Human Services, University of North Carolina, Public Health England.
AB - Background: There is much uncertainty about the risks of leukaemia and lymphoma after repeated or protracted low-dose radiation exposure typical of occupational, environmental, and diagnostic medical settings. We quantified associations between protracted low-dose radiation exposures and leukaemia, lymphoma, and multiple myeloma mortality among radiation-monitored adults employed in France, the UK, and the USA. Methods: We assembled a cohort of 308 297 radiation-monitored workers employed for at least 1 year by the Atomic Energy Commission, AREVA Nuclear Cycle, or the National Electricity Company in France, the Departments of Energy and Defence in the USA, and nuclear industry employers included in the National Registry for Radiation Workers in the UK. The cohort was followed up for a total of 8·22 million person-years. We ascertained deaths caused by leukaemia, lymphoma, and multiple myeloma. We used Poisson regression to quantify associations between estimated red bone marrow absorbed dose and leukaemia and lymphoma mortality. Findings: Doses were accrued at very low rates (mean 1·1 mGy per year, SD 2·6). The excess relative risk of leukaemia mortality (excluding chronic lymphocytic leukaemia) was 2·96 per Gy (90% CI 1·17-5·21; lagged 2 years), most notably because of an association between radiation dose and mortality from chronic myeloid leukaemia (excess relative risk per Gy 10·45, 90% CI 4·48-19·65). Interpretation: This study provides strong evidence of positive associations between protracted low-dose radiation exposure and leukaemia. Funding: Centers for Disease Control and Prevention, Ministry of Health, Labour and Welfare of Japan, Institut de Radioprotection et de SÛreté Nucléaire, AREVA, Electricité de France, National Institute for Occupational Safety and Health, US Department of Energy, US Department of Health and Human Services, University of North Carolina, Public Health England.
UR - http://www.scopus.com/inward/record.url?scp=84955727470&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84955727470&partnerID=8YFLogxK
U2 - 10.1016/S2352-3026(15)00094-0
DO - 10.1016/S2352-3026(15)00094-0
M3 - Article
C2 - 26436129
AN - SCOPUS:84955727470
SN - 2352-3026
VL - 2
SP - e276-e281
JO - The Lancet Haematology
JF - The Lancet Haematology
IS - 7
ER -